コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 /or predictive value of molecular markers in metastatic renal cell carcinoma.
2 mising to refine prognosis and prediction in metastatic renal cell carcinoma.
3 asculature, on tumor growth in patients with metastatic renal cell carcinoma.
4 candidate for controlling the progression of metastatic renal cell carcinoma.
5 nib as first-line treatment in patients with metastatic renal cell carcinoma.
6 tive to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma.
7 was low in previously treated patients with metastatic renal cell carcinoma.
8 preferred therapy for selected patients with metastatic renal cell carcinoma.
9 r-specific T-cell responses in subjects with metastatic renal cell carcinoma.
10 e of allogeneic stem cell transplantation in metastatic renal cell carcinoma.
11 TNP-470 in previously treated patients with metastatic renal cell carcinoma.
12 on as second-line treatment in patients with metastatic renal cell carcinoma.
13 of lenvatinib is warranted in patients with metastatic renal cell carcinoma.
14 T tracer of tumor perfusion in patients with metastatic renal cell carcinoma.
15 py remains controversial in the treatment of metastatic renal cell carcinoma.
16 ird-line targeted therapies in patients with metastatic renal cell carcinoma.
17 cond-line treatment option for patients with metastatic renal cell carcinoma.
18 ynergistic antitumor responses in a model of metastatic renal cell carcinoma.
19 rs of mTOR improve survival in patients with metastatic renal cell carcinoma.
20 era of targeted therapy in the management of metastatic renal cell carcinoma.
21 f rapamycin (mTOR), a therapeutic target for metastatic renal cell carcinoma.
22 the choice of therapies in the treatment of metastatic renal cell carcinoma.
23 utilized, when appropriate, in patients with metastatic renal cell carcinoma.
24 way inhibitor, is an effective treatment for metastatic renal-cell carcinoma.
25 endothelial growth factor, in patients with metastatic renal-cell carcinoma.
26 ients died during the study period, all from metastatic renal-cell carcinoma.
27 ious phase 3 studies involving patients with metastatic renal-cell carcinoma.
28 ration in previously untreated patients with metastatic renal-cell carcinoma.
29 h sorafenib in patients with treatment-naive metastatic renal-cell carcinoma.
30 nib dose titration in selected patients with metastatic renal-cell carcinoma.
31 plasma exposure correlates with efficacy in metastatic renal-cell carcinoma.
32 ictive of pazopanib benefit in patients with metastatic renal-cell carcinoma.
33 ast 7 years has extended median survival for metastatic renal-cell carcinoma.
34 in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the dru
35 ion until initiation of systemic therapy for metastatic renal-cell carcinoma; a decision that was mad
38 significant disease-stabilizing activity in metastatic renal cell carcinoma and is tolerable with ch
41 provide a survival benefit for patients with metastatic renal cell carcinoma and should be used in pa
42 s article reviews the role of nephrectomy in metastatic renal cell carcinoma and the optimal timing f
43 was disease progression in six patients with metastatic renal cell carcinoma and two patients with me
44 yvalent vaccine strategy in the treatment of metastatic renal cell carcinoma and, potentially, other
45 mproved overall survival among patients with metastatic renal-cell carcinoma and a poor prognosis.
46 T1b or greater with completely resected non-metastatic renal-cell carcinoma and adequate cardiac, re
47 nical use, extends survival of patients with metastatic renal-cell carcinoma and gastrointestinal str
48 ho received second-line targeted therapy for metastatic renal cell carcinoma at 19 centres in Canada,
49 s have not only revolutionized management of metastatic renal cell carcinoma but also created controv
50 toxicities and is feasible in patients with metastatic renal cell carcinoma but does not lead to any
52 graft-versus-tumor effects in patients with metastatic renal-cell carcinoma by means of nonmyeloabla
55 ee survival in patients with treatment-naive metastatic renal-cell carcinoma compared with those trea
56 e of molecular targeted systemic therapy for metastatic renal cell carcinoma, cure is uncommonly achi
58 intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium crit
60 molecular markers have been investigated in metastatic renal cell carcinoma for prognostic and/or pr
61 with treatment-naive, measurable, clear-cell metastatic renal-cell carcinoma from 13 countries were s
62 patients with treatment-naive, asymptomatic, metastatic renal-cell carcinoma from five hospitals in t
65 econd-line systemic therapy in patients with metastatic renal cell carcinoma have not been studied in
66 lled 750 patients with previously untreated, metastatic renal-cell carcinoma in a multicenter, random
67 lantation can induce sustained regression of metastatic renal-cell carcinoma in patients who have had
68 omly assigned 1110 patients with clear-cell, metastatic renal-cell carcinoma, in a 1:1 ratio, to rece
71 ough previously widely used for treatment of metastatic renal cell carcinoma, is still controversial,
72 lpha) as first-line therapy in patients with metastatic renal cell carcinoma (mRCC) (progression-free
74 he role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) has become unclea
76 s that predict the efficacy of everolimus in metastatic renal cell carcinoma (mRCC) patients are lack
78 ission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kin
79 e Sunitinib is a standard initial therapy in metastatic renal cell carcinoma (mRCC), but chronic dosi
84 have been many advances in the treatment of metastatic renal cell carcinoma of the clear cell type.
85 sure that adjusts prognosis of patients with metastatic renal-cell carcinoma on the basis of survival
90 ersus sorafenib as second-line treatment for metastatic renal cell carcinoma, patients given axitinib
91 In previous clinical trials of patients with metastatic renal-cell carcinoma, patients treated with a
92 ood mononuclear cells from 123 patients with metastatic renal cell carcinoma, prior to treatment, wer
100 of Tregs present in the peripheral blood of metastatic renal cell carcinoma (RCC) patients and abrog
103 factor tumor cell vaccines in patients with metastatic renal cell carcinoma (RCC) showed immune cell
104 a recent expansion of therapeutic options in metastatic renal cell carcinoma (RCC) targeted at the va
105 activity with a manageable safety profile as metastatic renal cell carcinoma (RCC) treatment, when gi
107 th metastatic breast cancer (BC) and 15 with metastatic renal cell carcinoma (RCC) underwent allogene
108 may help inform treatment choice in advanced/metastatic renal cell carcinoma (RCC), particularly betw
121 care for first-line treatment of advanced or metastatic renal-cell carcinoma (RCC); however, many pat
123 ase Consortium (IMDC) model in patients with metastatic renal cell carcinoma receiving next-line targ
126 urvival relative to placebo in patients with metastatic renal cell carcinoma that had progressed on o
127 ts with previously untreated, poor-prognosis metastatic renal-cell carcinoma to receive 25 mg of intr
128 e, 60.3 years; range, 19-83 years) with mRCC metastatic renal cell carcinoma treated with sunitinib f
129 original Choi criteria in patients with mRCC metastatic renal cell carcinoma treated with sunitinib.
130 iation--for prognostication in patients with metastatic renal-cell carcinoma treated with first-line
131 tiation of systemic therapy in patients with metastatic renal-cell carcinoma under active surveillanc
134 tment-naive patients diagnosed with advanced metastatic renal cell carcinoma were randomly allocated
135 ermore, NK cells expanded from patients with metastatic renal cell carcinoma were significantly more
137 omy has an established role in management of metastatic renal cell carcinoma when performed in proper
139 tomy in appropriately selected patients with metastatic renal cell carcinoma who are candidates for t
140 ole of IL-2, specimens from 15 patients with metastatic renal cell carcinoma who had been treated wit
141 sion-free survival benefit for patients with metastatic renal cell carcinoma who have progressed afte
142 unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on V
143 ntre phase 3 study, patients with clear cell metastatic renal cell carcinoma who received one previou
144 ineteen consecutive patients with refractory metastatic renal-cell carcinoma who had suitable donors
146 trolled trial of everolimus in patients with metastatic renal cell carcinoma whose disease had progre
147 ined the expected prognosis of patients with metastatic renal cell carcinoma with or without metastas
148 itinib, the standard first-line treatment in metastatic renal cell carcinoma with postulated favourab
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。